Creatine may cause hair loss in some individuals, especially those on finasteride, despite no scientific link. Personal experiences suggest individual sensitivity to DHT could be a factor.
PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.
ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.
The user has been taking finasteride for 1.5 years without seeing improvement in hair regrowth. Suggestions include adding minoxidil or switching to dutasteride, with concerns about side effects.
PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.
The user experienced significant hair regrowth using 0.5 mg Dutasteride and 5 mg oral Minoxidil daily, after initially using finasteride and a lower dose of Minoxidil. They are considering dermarolling or derma stamping to improve results further before opting for a hair transplant.
The user is considering switching from Finasteride to Dutasteride for better hair regrowth, despite concerns about potential shedding and side effects. Opinions vary, with some suggesting the switch for stronger results and others advising caution due to possible side effects and the importance of consulting a doctor.
Beard gains from minoxidil are usually permanent due to facial hair follicles' lower sensitivity to DHT. Scalp hair requires ongoing DHT suppression with treatments like finasteride, dutasteride, and RU58841 to maintain gains after stopping minoxidil.
Hair follicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.